SBI 1997

Drug Profile

SBI 1997

Alternative Names: SBI1997

Latest Information Update: 01 Mar 2016

Price : $50

At a glance

  • Originator Saronic Biotechnology
  • Class Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 25 Feb 2016 Preclinical data released by Saronic Biotechnology
  • 09 Feb 2016 Saronic Biotechnology plans a phase I/II trial in Hepatocellular carcinoma (Adjuvant therapy) in USA in 2016
  • 29 Dec 2015 Saronic Biotechnology plans a Compassionate Patient Access programme in Hepatocellular carcinoma (Late-stage disease) in USA (Saronic Biotechnology pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top